Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury

Stock Monitor: Stellar Biotechnologies Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Asterias Biotherapeutics, Inc. (NYSE: AST) (“Asterias”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AST. On December 19, 2017, the Company announced the enrollment and dosing of the last subject in its SciStar Phase-1/2a clinical study of AST-OPC1 in motor complete cervical spinal cord injury (SCI). Asterias, a biotechnology Company specializing in the field of regenerative medicine, has enrolled a total of 25 subjects in the SciStar study, plus 5 subjects from a previous Phase-1 safety trial. There are currently no approved therapies that improve the recovery of neurological function after suffering a severe SCI. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Stellar Biotechnologies, Inc. (NASDAQ: SBOT), which also belongs to the Healthcare sector as the Company Asterias Biotherapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SBOT

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Asterias Biotherapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AST

About The SciStar Trial

The SciStar trial is an open-label, single-arm study to test three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) SCI. The individuals in the trial had essentially lost all movement below the injury site and as a consequence, faced severe paralysis of the upper and lower limbs.

AIS-A patients have lost all motor and sensory functions of the body below the injury site, while AIS-B patients lost all motor functions, but may have retained some minimal sensory function below the injury site. AST-OPC1, according to Asterias, is being administered 21 to 42 days post the injury. Patients under the trial will be followed by neurological exams and imaging procedures to access the safety and the potential activity of the product.

About AST-OPC1

AST-OPC1 is an oligodendrocyte progenitor population, which was originally isolated in 1998, and is derived from human embryonic stem cells. The progenitor has been tested in vitro and in animals, where it had three potential reparative functions to address the complex pathologies originating at the site of a SCI. The activities of the progenitor from Asterias include production of neurotrophic factors, stimulation of vascularization, and induction of remyelination of denuded axons, which are critical for survival, regrowth, and conduction of nerve impulses through axons at the injury site.

Recently, in the Phase-1 clinical trial, five patients with SCI were administered two million AST-OPC1 cells at the injury site, 7 to 14 days after the injury. Owing to the successful end-results of the study, the Company received the US Food and Drug Administration (FDA) clearance to proceed with the testing of AST-OPC1 to patients with cervical spine injuries in the current SciStar study.

Future Prospects

According to the Company, severe SCIs can be devastating to the quality of life and the ability to function independently, without any aid. Lifetime healthcare and assistance costs over $5 million for these patients in the absence of any approved therapies to treat severe SCI. In October 2017, Asterias reported the 12-month data from the study’s Cohort-2 (AIS-A 10 million-cell cohort), including six subjects.

By 12 months, 67% of Cohort-2 subjects recovered 2 or more motor levels on at least one side, hence elevating the Company’s 12-month target of 45% – 50% of subjects achieving the threshold of improvement. The Company intends to report a 6-month data from Cohort-3 (AIS-A 20 million-cell cohort) and Cohort-4 (AIS-B 10 million-cell cohort) in February 2018, and the 12-month data from Cohorts-3 and -4 in August 2018. Also, Asterias expects to report the six-month top-line readout for the entire study in June 2018, and the 12-month top-line readout for the entire study in December 2018.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Asterias Biotherapeutics’ stock dropped 2.27%, ending the trading session at $2.15.

Volume traded for the day: 113.10 thousand shares.

After yesterday’s close, Asterias Biotherapeutics’ market cap was at $121.93 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484755